BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
Asian Markets Mixed as RBI Cuts Rates and BOJ Signals Possible Hike 
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
